Medicinal preparation based on fetal cell suspension having immune substituting effect for patients with acquired immune deficiency syndrome (HIV infection)

A pharmaceutical composition for administration to a human having acquired immune deficiency syndrome caused by HIV-infection, which comprises:

• a cell suspension from a single human embryo having a gestation of seven weeks or less wherein said cell suspension is selected from the group consisting of human hematopoietic liver cells, human hematopoietic spleen cells and a mixture of human hematopoietic liver and spleen cells;
• and in which the contents of nucleated cells is 5 to 200×106;
• the contents of colony-forming units of granulocyte/macrophage (CFU-GM) is 20 to 200×103/ml;
• the contents of colony-forming units of granulocyte, erythrocyte, monocytelmacrophage, megakaryocyte (CFU-GEMM) is 0.5 to 50×103/ml;
• and the contents of progenitor cells is (CD 34) 1 to 20×106/ml.